Outcomes improving for younger patients with follicular lymphoma
the ONA take:
Patients younger than 40 years with follicular lymphoma have a median overall survival of 24 years and their outcome seems to be improving over time, according to a recent study published online ahead of print in the journal Annals of Oncology.
For the study, investigators sought to evaluate the clinical features and outcomes of younger patients with follicular lymphoma.
Researchers retrospectively analyzed data from 1,002 patients with follicular lymphoma diagnosed in Spain, Switzerland, United Kingdom, or Italy between 1985 and 2010.
Results showed that at a median follow-up of 10 years, younger patients had significantly better overall survival, cause-specific survival, and progression-free survival compared with those older than 40 years.
Researchers found that patients with a lymphoma diagnosis in the last two decades and having a Follicular Lymphoma International Prognostic Index (FLIPI) score were associated with a significantly longer progression-free survival and cause-specific survival in patients younger than 40 years. A favorable FLIPI score was significantly associated with longer overall survival.
Patients younger than 40 years with follicular lymphoma have a median overall survival of 24 years.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|